Literature DB >> 22195532

Frailty and respiratory impairment in older persons.

Carlos A Vaz Fragoso1, Paul L Enright, Gail McAvay, Peter H Van Ness, Thomas M Gill.   

Abstract

BACKGROUND: Among older persons, the association between frailty and spirometry-confirmed respiratory impairment has not been evaluated yet.
METHODS: By using data on white participants aged 65 to 80 years (Cardiovascular Health Study, N=3578), we evaluated cross-sectional and longitudinal associations between frailty and respiratory impairment, including their combined effect on mortality. Baseline assessments included frailty status (Fried phenotype: non-frail, pre-frail, and frail) and spirometry. Outcomes included development of frailty features (pre-frail or frail) at year 3 and respiratory impairment (airflow limitation or restrictive pattern) at year 4, and death (median follow-up, 13.2 years).
RESULTS: At baseline, 48.3% of participants were pre-frail, 5.8% of participants were frail, 13.8% of participants had airflow limitation, and 9.3% of participants had restrictive pattern; 46.1% of participants subsequently died. At baseline, pre-frail and frail were cross-sectionally associated with airflow limitation (adjusted odds ratio [OR], 1.62; 95% confidence interval [CI], 1.29-2.04 and adjusted OR 1.88; 95% CI, 1.15-3.09) and restrictive pattern (adjusted OR, 1.80; 95% CI, 1.37-2.36 and adjusted OR, 3.05; 95% CI, 1.91-4.88), respectively. Longitudinally, participants with baseline frailty features had an increased likelihood of developing respiratory impairment (adjusted OR, 1.42; 95% CI, 1.11-1.82). Conversely, participants with baseline respiratory impairment had an increased likelihood of developing frailty features (adjusted OR, 1.58; 95% CI, 1.17-2.13). Mortality was highest among participants who were frail and had respiratory impairment (adjusted hazard ratio, 3.91; 95% CI, 2.93-5.22), compared with those who were non-frail and had no respiratory impairment.
CONCLUSION: Frailty and respiratory impairment are strongly associated with one another and substantially increase the risk of death when both are present. Establishing these associations may inform interventions designed to reverse or prevent the progression of either condition and to reduce adverse outcomes. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22195532      PMCID: PMC3246194          DOI: 10.1016/j.amjmed.2011.06.024

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  43 in total

Review 1.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-01-15       Impact factor: 21.405

2.  Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease.

Authors:  M Dahl; A Tybjaerg-Hansen; J Vestbo; P Lange; B G Nordestgaard
Journal:  Am J Respir Crit Care Med       Date:  2001-09-15       Impact factor: 21.405

Review 3.  Management of chronic obstructive pulmonary disease.

Authors:  E Rand Sutherland; Reuben M Cherniack
Journal:  N Engl J Med       Date:  2004-06-24       Impact factor: 91.245

4.  Defining chronic obstructive pulmonary disease in an aging population.

Authors:  Carlos A Vaz Fragoso; Thomas M Gill
Journal:  J Am Geriatr Soc       Date:  2010-11       Impact factor: 5.562

5.  Predictors of loss of lung function in the elderly: the Cardiovascular Health Study.

Authors:  K A Griffith; D L Sherrill; E M Siegel; T A Manolio; H W Bonekat; P L Enright
Journal:  Am J Respir Crit Care Med       Date:  2001-01       Impact factor: 21.405

6.  Reductions in functional balance, coordination, and mobility measures among patients with stable chronic obstructive pulmonary disease.

Authors:  Scott J Butcher; Jaclyn M Meshke; M Suzanne Sheppard
Journal:  J Cardiopulm Rehabil       Date:  2004 Jul-Aug       Impact factor: 2.081

7.  Cognitive impairment in chronic obstructive pulmonary disease--a neuropsychological and spect study.

Authors:  Raffaele Antonelli Incalzi; Camillo Marra; Alessandro Giordano; Maria Lucia Calcagni; Antonella Cappa; Salvatore Basso; Gabriella Pagliari; Leonello Fuso
Journal:  J Neurol       Date:  2003-03       Impact factor: 4.849

8.  Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study.

Authors:  P Buch; J Friberg; H Scharling; P Lange; E Prescott
Journal:  Eur Respir J       Date:  2003-06       Impact factor: 16.671

Review 9.  Chronic obstructive pulmonary disease as a systemic disease: an epidemiological perspective.

Authors:  H Andreassen; J Vestbo
Journal:  Eur Respir J Suppl       Date:  2003-11

10.  Thoracic kyphosis and ventilatory dysfunction in unselected older persons: an epidemiological study in Dicomano, Italy.

Authors:  Mauro Di Bari; Melisenda Chiarlone; Daniela Matteuzzi; Simona Zacchei; Claudia Pozzi; Vincenzo Bellia; Francesca Tarantini; Riccardo Pini; Giulio Masotti; Niccoló Marchionni
Journal:  J Am Geriatr Soc       Date:  2004-06       Impact factor: 5.562

View more
  56 in total

1.  Mitochondrial DNA variants and pulmonary function in older persons.

Authors:  Carlos A Vaz Fragoso; Todd M Manini; John A Kairalla; Thomas W Buford; Fang-Chi Hsu; Thomas M Gill; Stephen B Kritchevsky; Mary M McDermott; Jason L Sanders; Steven R Cummings; Gregory J Tranah
Journal:  Exp Gerontol       Date:  2018-12-01       Impact factor: 4.032

2.  Spirometry, Static Lung Volumes, and Diffusing Capacity.

Authors:  Carlos A Vaz Fragoso; Hilary C Cain; Richard Casaburi; Patty J Lee; Lynne Iannone; Linda S Leo-Summers; Peter H Van Ness
Journal:  Respir Care       Date:  2017-07-11       Impact factor: 2.258

3.  Frailty and Clinical Outcomes in Chronic Obstructive Pulmonary Disease.

Authors:  Cassie C Kennedy; Paul J Novotny; Nathan K LeBrasseur; Robert A Wise; Frank C Sciurba; Roberto P Benzo
Journal:  Ann Am Thorac Soc       Date:  2019-02

Review 4.  Sarcopenia and frailty in chronic respiratory disease.

Authors:  Anna E Bone; Nilay Hepgul; Samantha Kon; Matthew Maddocks
Journal:  Chron Respir Dis       Date:  2017-02-24       Impact factor: 2.444

5.  Respiratory impairment and dyspnea and their associations with physical inactivity and mobility in sedentary community-dwelling older persons.

Authors:  Carlos A Vaz Fragoso; Daniel P Beavers; John L Hankinson; Gail Flynn; Kathy Berra; Stephen B Kritchevsky; Christine K Liu; Mary M McDermott; Todd M Manini; W Jack Rejeski; Thomas M Gill
Journal:  J Am Geriatr Soc       Date:  2014-03-17       Impact factor: 5.562

6.  Respiratory impairment and COPD hospitalisation in older persons: a competing risk analysis.

Authors:  Carlos A Vaz Fragoso; John Concato; Gail McAvay; Peter H Van Ness; Thomas M Gill
Journal:  Eur Respir J       Date:  2012-01-20       Impact factor: 16.671

Review 7.  Frailty in Pulmonary and Critical Care Medicine.

Authors:  Jonathan P Singer; David J Lederer; Matthew R Baldwin
Journal:  Ann Am Thorac Soc       Date:  2016-08

Review 8.  Respiratory impairment and the aging lung: a novel paradigm for assessing pulmonary function.

Authors:  Carlos A Vaz Fragoso; Thomas M Gill
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-12-01       Impact factor: 6.053

9.  Effect of coexisting chronic obstructive pulmonary disease and cognitive impairment on health outcomes in older adults.

Authors:  Sandy S Chang; Shu Chen; Gail J McAvay; Mary E Tinetti
Journal:  J Am Geriatr Soc       Date:  2012-10-04       Impact factor: 5.562

Review 10.  Multimorbidity and functional impairment-bidirectional interplay, synergistic effects and common pathways.

Authors:  A Calderón-Larrañaga; D L Vetrano; L Ferrucci; S W Mercer; A Marengoni; G Onder; M Eriksdotter; L Fratiglioni
Journal:  J Intern Med       Date:  2018-11-22       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.